CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine

References

• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol.33, 48–56 (1993).
   PubMed Web of Science ®Google Scholar
• Haerter K, Ayata C, Moskowitz MA. Cortical spreading depression: a model for understanding migraine biology and future drug targets. Headache Curr.2(5), 97–103 (2005).
   Google Scholar
• Takano T, Tian G-F, Peng W et al. Cortical spreading depression causes and coincides with tissue hypoxia. Nat. Neurosci.10(6), 754–762 (2007).
   PubMed Web of Science ®Google Scholar
• Iadecola C. From CSD to headache: a long and winding road. Nat. Med.8, 110–112 (2002).
   PubMed Web of Science ®Google Scholar
• Gorji A. Spreading depression: a review of the clinical relevance. Brain Res. Rev.38, 33–60 (2001).
   PubMed Web of Science ®Google Scholar
• Somjen GG. Mechanisms of spreading depression and hypoxic spreading-depression like depolarization. Physiol. Rev.81(3), 1065–1096 (2001).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache48, 7–15 (2008).
   Google Scholar
• Leão AAP. Spreading depression of activity in cerebral cortex. J. Neurophysiol.7, 359–390 (1944).
   Google Scholar
• Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch. Neurol. Psychiatry46, 259–264 (1941).
   Google Scholar
• Blau JN. Migraine: theories of pathogenesis. Lancet339, 1202–1207 (1992).
   PubMed Web of Science ®Google Scholar
• Gloor P. Migraine and regional cerebral blood flow. Trends Neurosci.21, 9 (1986).
   Google Scholar
• Pearce JMS. Is migraine explained by Leão’s spreading depression? Lancet2(8458), 763–766 (1985).
   Google Scholar
• Gupta VK. Adaptive Mechanisms in Migraine – A Conceptual Synthesis in Evolution. Breaking the Migraine Code. Nova Science, NY, USA (2009).
   Google Scholar
• Olsen TS. Is it really true that spreading depression is the cause of the migraine aura? News Headache4(2), 7 (1994).
   Google Scholar
• Maranhão-Filho P, Vincent M. Professor Aristides Leão. Much more than spreading depression. Headache49, 110–116 (2009).
   Google Scholar
• Thompson CS, Hakim AM. Cortical spreading depression modifies components of the inflammatory cascade. Mol. Neurobiol.32, 51–58 (2005).
   Google Scholar
• Yanamoto H, Miyamoto S, Tohnai N et al. Induced spreading depression activates persistent neurogenesis in the subventricular zone, generating cells with markers for divided and early committed neurons in the caudate putamen and cortex. Stroke36, 1544–1550 (2005).
   PubMedGoogle Scholar
• Oton T, Greenberg JH, Welsh FA. Cortical spreading depression causes a long-lasting decrease in cerebral blood flow and induces tolerance to permanent focal ischemia in rat brain. J. Cereb. Blood. Flow. Metab.23, 43–50 (2003).
   Google Scholar
• Woods R, Iacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N. Eng. J. Med.331, 1689–1692 (1994).
   PubMed Web of Science ®Google Scholar
• Hadjikhani N, Sanchez del Rio M, Wu O. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad. Sci. USA98, 4687–4692 (2001).
   PubMed Web of Science ®Google Scholar
• Bowyer SM, Aurora KS, Moran JE, Tepley N, Welch KM. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann. Neurol.50, 582–587 (2001).
   PubMed Web of Science ®Google Scholar
• Gorji A, Scheller D, Straub H et al. Spreading depression in human neocortical slices. Brain Res.906, 74–83 (2001).
   PubMed Web of Science ®Google Scholar
• Mayevsky A, Doron A, Manor T et al. Cortical spreading depression recorded from human brain using a multiparametric monitoring system. Brain Res.740, 268–274 (1996).
   PubMed Web of Science ®Google Scholar
• Strong AJ, Fabricus M, Boutelle MG et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke33, 2738–2743 (2002).
   PubMed Web of Science ®Google Scholar
• Fabricius M, Fuhr S, Bhatia R et al. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain129, 778–790 (2006).
   PubMed Web of Science ®Google Scholar
• Dreier JP, Major S, Manning A et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain132(Pt 7), 1866–1881 (2009).
   PubMed Web of Science ®Google Scholar
• Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain117, 199–210 (1994).
   PubMed Web of Science ®Google Scholar
• Olesen J, Friberg L, Olsen TS et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol.28, 791–798 (1990).
   PubMed Web of Science ®Google Scholar
• Lauritzen M, Olesen J. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain107, 447–461 (1984).
   PubMed Web of Science ®Google Scholar
• Gelmers HJ. Common migraine attacks preceded by focal hyperemia and parietal oligemia in the rCBF pattern. Cephalalgia2, 29–32 (1982).
   PubMed Web of Science ®Google Scholar
• Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann. Neurol.9, 344–352 (1981).
   PubMed Web of Science ®Google Scholar
• Olsen TS, Friberg L, Lassen NA. Ischemia may be the primary cause of the neurological deficits in classic migraine. Arch. Neurol.44, 156–161 (1987).
   Google Scholar
• Olsen TS, Lassen NA. Blood flow and vascular reactivity during attacks of classic migraine – limitations of the Xe-133 intraarterial technique. Headache29, 15–20 (1989).
   PubMed Web of Science ®Google Scholar
• Olsen TS. Spreading oligemia in the migraine aura – most likely an artifact due to scattered radiation. Cephalalgia13, 86–88 (1993).
   PubMed Web of Science ®Google Scholar
• Kobari M, Meyer JS, Ichijo M, Imai A, Oravez WT. Hyperperfusion of cerebral cortex, thalamus and basal ganglia during spontaneously occurring migraine headaches. Headache29, 282–289 (1989).
   PubMed Web of Science ®Google Scholar
• Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med.8, 136–142 (2002).
   PubMed Web of Science ®Google Scholar
• Maxner CE, Moeller JJ. Visual disturbances and migraine. Curr. Neurol. Neurosci. Rep.5, 376–381 (2005).
   Google Scholar
• Chronicle EP, Mulleners WM. Visual system dysfunction in migraine: a review of clinical and psychophysical findings. Cephalalgia16, 525–535 (1996).
   PubMed Web of Science ®Google Scholar
• Hupp SL, Kline LB, Corbett JJ. Visual disturbances of migraine. Surv. Ophthalmol.33, 221–236 (1989).
   Web of Science ®Google Scholar
• Campbell JK. Manifestations of migraine. Neurol. Clin.8, 841–855 (1990).
   PubMed Web of Science ®Google Scholar
• Martins-Ferreira H. Spreading depression in the chick retina. In: The brain and behaviour of the fowl. Okawa T (Ed.). Japanese Societies Press, Tokyo, Japan 317–333 (1983).
   Google Scholar
• Bures J, Buresova O, Krivanek J. The Mechanism and Applications of Leão’s Spreading Depression of Electroencephalographic Activity. Academia, Prague, Czech Republic (1974).
   Google Scholar
• Vanopdenbosch L, Horroelen L. Leão’s cortical spreading depression and the somatosensory homunculus: a contradiction? Headache38, 322–323 (1998).
   Google Scholar
• Gotoh F, Komatsumoto S, Araki N, Gomi S. Noradrenergic nervous activity in migraine. Arch. Neurol.41, 951–955 (1984).
   PubMedGoogle Scholar
• Havanka-Kannianen H, Tolonen U, Myllyla VV. Autonomic dysfunction in adult migraineurs. Headache26, 425–430 (1986).
   Google Scholar
• Shechter A, Stewart WF, Silberstein SD, Lipton RB. Migraine and autonomic nervous system function. A population-based, case–control study. Neurology58, 422–427 (2002).
   Google Scholar
• Moskowitz MA, Bolay H, Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann. Neurol.55(2), 276–280 (2004).
   Google Scholar
• Ferrari MD. Migraine genetics: a fascinating journey towards improved migraine therapy. Headache48(5), 697–700 (2008).
   Google Scholar
• Gursoy-Ozdemir Y, Qiu J, Matsuoka N et al. Cortical spreading depression activates and upregulates MMP-9. J. Clin. Invest.113, 1447–1455 (2004).
   PubMed Web of Science ®Google Scholar
• Nedergaard M, Hansen AJ. Spreading depression is not associated with neuronal injury in the normal brain. Brain Res.24, 395–398 (1988).
   Google Scholar
• Lian XY, Stringer JL. Energy failure in astrocytes increases the vulnerability of neurons to spreading depression. Eur. J. Neurosci.19, 2446–2454 (2004).
   Google Scholar
• Gaist D, Pedersen L, Madsen C et al. Long-term effects of migraine on cognitive function. A population-based study of Danish twins. Neurology64, 600–607 (2005).
   PubMed Web of Science ®Google Scholar
• Friedman AP. Headache. In: Clinical Neurology. Baker AB, Joynt RJ (Eds). Harper & Row, PA, USA 1–50 (1985).
   Google Scholar
• Koroleva VI, Bures J. Rats do not experience cortical or hippocampal spreading depression as aversive. Neurosci. Lett.149, 153–156 (1993).
   Google Scholar
• Huston JP, Jan Bures J. Drinking and eating elicited by cortical spreading depression. Science169, 702–704 (1970).
   Google Scholar
• Carew TJ, Crow TJ, Petrinovich LF. Lack of coincidence between neural and behavioral manifestations of cortical spreading depression. Science169, 1339–1342 (1970).
   Google Scholar
• Monda M, Pittman QJ. Cortical spreading depression blocks prostaglandin E1 and endotoxin fever in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol.264, R456–R459 (1993).
   Google Scholar
• Read SJ, Smith MI, Benham CD, Hunter AJ, Parsons AA. Furosemide inhibits regenerative cortical spreading depression in anesthetized cats. Cephalalgia17, 826–832 (1997).
   Google Scholar
• de Almeida RF, Leão IAT, Gomes JBL, da Silva Jr AA, Teixeira AL. Migraine with persistent visual aura: response to furosemide. Clinics (Sao Paulo)64(4), 375–376 (2009).
   Google Scholar
• Rozen TD. Treatment of a prolonged migrainous aura with intravenous furosemide. Neurology55(5), 732–733 (2000).
   Google Scholar
• Kaube H, Goadsby PJ. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur. Neurol.34, 30–35 (1994).
   PubMed Web of Science ®Google Scholar
• Alemdar M, Akman Ö, Selekler HM, Komsuoglu SS, Ates N. Does metoprolol inhibit the cortical spreading depression? Acute effects of systematic metropol on CSD in rats. Cephalalgia27, 1010–1013 (2007).
   PubMed Web of Science ®Google Scholar
• Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol.59, 652–661 (2006).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N. Engl. J. Med.346, 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• Lampl C, Bonelli S, Ransmayr G. Efficacy of topiramate in migraine aura prophylaxis: preliminary results of 12 patients. Headache44, 174–176 (2004).
   PubMed Web of Science ®Google Scholar
• Piper RD, Edvinsson L, Ekman R, Lambert GA. Cortical spreading depression does not result in the release of calcitonin-gene related peptide into the external jugular vein of the cat: relevance to human migraine. Cephalalgia13, 180–183 (1993).
   Google Scholar
• Guedes RC, Cavalthreiro EA. Blockade of spreading depression in chronic epileptic rats. Epilepsy Res.27, 133–136 (1997).
   Google Scholar
• Sacco RL, DeRossa JT, Haley EC Jr et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA285, 1719–1728 (2001).
   PubMed Web of Science ®Google Scholar
• Lees KR, Asplund K, Carolei A et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomized controlled trial. GAIN International Investigators 10. Lancet355, 1949–1954 (2000).
   PubMed Web of Science ®Google Scholar
• Heiss WD, Thiel A, Grond M, Graf R. Which targets are relevant for therapy of acute ischemic stroke? Stroke30, 1486–1489 (1999).
   PubMed Web of Science ®Google Scholar
• Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J. Neurosci.13, 1167–1177 (1993).
   PubMed Web of Science ®Google Scholar
• Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ. Possible mechanism of c-fos expression in trigeminal nucleus caudalis following cortical spreading depression. Pain72, 407–415 (1997).
   PubMed Web of Science ®Google Scholar
• Ebersberger A, Schaible H-G, Averbeck B, Richter F. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann. Neurol.49, 7–13 (2001).
   PubMed Web of Science ®Google Scholar
• Lambert GA, Michalicek J, Storer RJ, Zagami AS. Effect of cortical spreading depression on activity of trigeminovascular sensory neurons. Cephalalgia19, 631–638 (1999).
   Google Scholar
• Bartsch T. Migraine and the neck: new insights from basic data. Curr. Pain Headache Rep.9, 191–196 (2005).
   PubMedGoogle Scholar
• Campbell JK. Facial pain due to migraine and cluster headache. Semin. Neurol.8, 324 (1988).
   Google Scholar
• Bannister LH, Berry MM, Collins P, Dyson M, Dussek JE, Ferguson MWJ. Gray’s Anatomy (38th Edition). Churchill Livingstone, NY, USA 1232 (1995).
   Google Scholar
• Bohotin V, Fumal A, Vandenheede M, Bohotin C, Schoenen J. Excitability of visual V1–V2 and motor cortices to single transcranial magnetic stimuli in migraine: a reappraisal using a figure-of-eight coil. Cephalalgia23, 264–270 (2003).
   PubMed Web of Science ®Google Scholar
• Chronicle EP, Mulleners WM, Palmer JE, Vredeveld JW, Koehler PJ. Transcranial magnetic stimulation confirms visual cortical hyperexcitability in migraine, but response to valproate is variable. Neurology54(Suppl. 3), (2000) (Abstract A128).
   Google Scholar
• Schatzberg AF, Nemeroff CB. Essentials of Clinical Psychopharmacology (2nd Edition). American Psychiatric Publishers, DC, USA 12–13 (2006).
   Google Scholar
• Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology45, 219–223 (1995).
   PubMed Web of Science ®Google Scholar
• Shulman BH. Psychiatric aspects of headache. Med. Clin. North Am.75, 707–715 (1991).
   Google Scholar
• Jarcho S. General Grant’s headache. Bull. NY Acad. Med.43, 1224–1226 (1967).
   Google Scholar
• Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol.47, 614–624 (2000).
   PubMed Web of Science ®Google Scholar
• Dahlöf C. Cutaneous allodynia and migraine: another view. Curr. Pain Headache Rep.10(3), 231–238 (2006).
   PubMedGoogle Scholar
• Lovati C, D’Amico, Bertora P et al. Acute and interictal allodynia in patients with different headache forms: an Italian pilot study. Headache48(2), 272–277 (2008).
   PubMed Web of Science ®Google Scholar
• Young WB, Gangal KS, Aponte RJ, Kaiser RS. Migraine with unilateral motor symptoms (MUMS): a case control study. J. Neurol. Neurosurg. Psychiatry78, 600–604 (2006).
   Google Scholar
• Lovati C, D’Amico D, Bertora P. Allodynia in migraine: frequent random association or unavoidable consequence? Exp. Rev. Neurother.9(3), 395–408 (2009).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Young WB. Migraine aura and prodrome. Semin. Neurol.15, 175–182 (1995).
   PubMed Web of Science ®Google Scholar
• Cruickshank JM, Neil-Dwyer G. β-blocker brain concentrations in man. Eur. J. Clin. Pharm.28(Suppl.), 21–23 (1985).
   PubMedGoogle Scholar
• Emilien G, Maloteaux JM. Current therapeutic uses and potential of β-adrenoceptor agonists and antagonists. Eur. J. Clin. Pharmacol.53, 389–404 (1998).
   Google Scholar
• Stensrud P, Sjaastad O. Comparative trial of tenormin (atenolol) and inderal (propranolol) in migraine. Upsala J. Med. Sci. Suppl.31, 37–40 (1980).
   Google Scholar
• Gupta VK. Pharmacotherapeutics of migraine and the blood–brain barrier: serendipity, empiricism, hope, and hype. Med. Gen. Med.8(2), 89 (2006).
   Google Scholar
• Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation – a 3T magnetic resonance angiography study. Brain131, 2192–2200 (2008).
   PubMed Web of Science ®Google Scholar
• de Tommaso M, Libro G, Guido M et al. Nitroglycerin induces migraine headache and central sensitization phenomena in patients with migraine without aura: a study of laser evoked potentials. Neurosci. Lett.363, 272–275 (2004).
   PubMed Web of Science ®Google Scholar
• Read SJ, Smith MI, Hunter AJ, Parsons AA. The dynamics of nitric oxide release measured directly and in real time following repeated waves of cortical spreading depression in the anaesthetized cats. Neurosci. Lett.232, 127–130 (1997).
   PubMed Web of Science ®Google Scholar
• Obrenovitch TP, Urenjak J, Wang M. Nitric oxide formation during cortical spreading depression is critical for rapid subsequent recovery of ionic homeostasis. J. Cereb. Blood. Flow. Metab.22, 680–688 (2002).
   PubMed Web of Science ®Google Scholar
• Colonna DM, Meng W, Deal DD, Gowda M, Busija DW. Neuronal NO promotes cerebral cortical hyperemia during cortical spreading depression in rabbits. Am. J. Physiol.272(3 Pt 2), H1315–H1322 (1997).
   Google Scholar
• Ulmer HJ, de Lima VM, Hanke W. Effects of nitric oxide on the retinal spreading depression. Brain Res.691, 239–242 (1995).
   Google Scholar
• Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain110, 675–680 (2004).
   PubMed Web of Science ®Google Scholar
• Afridi S, Kaube H, Goadsby PJ. Occipital activation in glyceryl trinitrate induced migraine with visual aura. J. Neurol. Neurosurg. Psychiatry76, 1158–1160, (2005).
   PubMedGoogle Scholar
• Bonuso S, Marano E, Stasio ED, Sorge F, Barbieri F, Ullucci E. Source of pain and primitive dysfunction in migraine: an identical site? J. Neurol. Neurosurg. Psychiatry52, 1351–1354 (1989).
   Google Scholar
• McArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ. Nifedipine in the prophylaxis of classic migraine. Neurology39, 284–285 (1989).
   Google Scholar
• Diener H-C, Scholz E, Dichgans J et al. Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials. Ann. Neurol.25, 125–130 (1989).
   PubMed Web of Science ®Google Scholar
• Dahlem MA, Chronicle EP. A computational perspective on migraine aura. Prog. Neurobiol.74, 351–361 (2004).
   Google Scholar
• Fuller GN, Gale MV. Migraine aura as artistic inspiration. BMJ297, 1670–1672 (1988).
   PubMed Web of Science ®Google Scholar
• Van Der Hel WS, Van Den Bergh WM, Nicolay K, Tulleken KAF, Dijkhuizen RM. Suppression of cortical spreading depressions after magnesium treatment in the rat. Neuroreport9, 2179–2182 (1998).
   PubMed Web of Science ®Google Scholar
• Welch KMA, D’Andrea G, Teply N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol. Clin.8, 817–828 (1990).
   PubMed Web of Science ®Google Scholar
• Durlach J, Pagès N, Bac P, Bara M. Guiet-Bara A. Headache due to photosensitive magnesium depletion. Magnes. Res.18, 109–122 (2005).
   Google Scholar
• Frank LR, Olson CM, Shuler KB, Gharib SF. Intravenous magnesium for acute benign headache in the emergency department: a randomized double-blind placebo-controlled trial. Can. J. Emerg. Med.6, 327–332 (2004).
   Google Scholar
• Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache43, 601–610 (2003).
   PubMed Web of Science ®Google Scholar
• Ko SH, Lim HR, Kim DC, Han, YJ, Choe, H, Song HS. Magnesium sulphate does not reduce postoperative analgesic requirements. Anesthesiology95, 640–646 (2001).
   PubMed Web of Science ®Google Scholar
• Esen F, Erdem T, Aktan D et al. Effect of magnesium sulfate administration on blood–brain barrier in a rat model of intraperitoneal sepsis: a randomized controlled experimental study. Crit. Care9, R18–R23 (2005).
   PubMedGoogle Scholar
• Kaya M, Gulturk S, Elmas I et al. The effects of magnesium sulfate on blood–brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Life Sci.76, 201–212 (2004).
   Google Scholar
• Esen F, Erdem T, Aktan D et al. Effects of magnesium administration on brain edema and blood–brain barrier breakdown after experimental traumatic brain injury in rats. J. Neurosurg. Anesthesiol.15, 119–125 (2003).
   PubMed Web of Science ®Google Scholar
• Kaya M, Küçük M, Kalayci RB et al. Magnesium sulfate attenuates increased blood–brain barrier permeability during insulin-induced hypoglycemia in rats. Can. J. Physiol. Pharmacol.79, 793–798 (2001).
   PubMed Web of Science ®Google Scholar
• Altura BT, Altura BM. The role of magnesium in etiology of strokes and cerebrovasospasm. Magnesium1, 277–291 (1982).
   Google Scholar
• Durlach J. Neurological manifestations of magnesium imbalance. Handbook Clin. Neurol.28, 545–579 (1976).
   Google Scholar
• Jain AL, Sethi NC, Babbar PK. A clinical electroencephalographic and trace element study with special reference to zinc, copper, and magnesium in serum and cerebrospinal fluid (CSF) in cases of migraine. J. Neurol. Suppl.232, 161 (1985).
   Google Scholar
• Wong ET, Rude RK, Singer FR, Shaw ST. A high prevalence of hypomagnesemia and hypermagnesemia in hospitalized patients. Am. J. Clin. Path.79, 348–352 (1983).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia17, 109–112 (1997).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D. For the MIGR-001 study group. Topiramate in migraine prevention. Arch. Neurol.61, 490–495 (2004).
   PubMed Web of Science ®Google Scholar
• Láinez MJA, Pascual J, Pascual AM, Santonja JM, Ponz A, Salvador A. Topiramate in the prophylactic treatment of cluster headache. Headache43, 784–789 (2003).
   PubMed Web of Science ®Google Scholar
• De Simone R, Marano E, Di Stasio E, Bonuso S, Fiorillo C, Bonavita V. Acetazolamide efficacy and tolerability in migraine with aura: a pilot study. Headache45, 385–386 (2005).
   PubMed Web of Science ®Google Scholar
• Spacey SD, Hildebrand ME, Materek LA, Bird TD, Snutch TP. Functional implications of a novel EA2 mutation in the P/Q-type calcium channel. Ann. Neurol.56, 213–220 (2004).
   PubMed Web of Science ®Google Scholar
• Murphy VA, Johanson CE. Acidosis, acetazolamide, and amiloride: effects on 22 Na transfer across the blood–brain and blood–CSF barriers. J. Neurochem.52, 1058–1063 (1989).
   Google Scholar
• Ptácek LJ. Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Neuromuscul. Disord.7, 250–255 (1997).
   PubMed Web of Science ®Google Scholar
• Hess EJ. Migraines in mice? Cell87, 1149–1151 (1996).
   Google Scholar
• Bannwarth B, Schaeverbeke T, Péhourcq F, Vernhes JP, D’Yvoire MB, Dehais J. Prednisolone concentrations in cerebrospinal fluid after oral prednisolone. Preliminary data. Rev. Rheum. Engl. Ed.64, 301–304 (1997).
   PubMedGoogle Scholar
• Miettinen S, Fusco FR, Yrjänheikki J et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc. Natl Acad. Sci. USA Neurobiology94, 6500–6505 (1997).
   PubMed Web of Science ®Google Scholar
• Rozen TD. Migraine headache: immunosuppressant therapy. Curr. Treat. Opt. Neurol.4, 395–401 (2007).
   Google Scholar
• Prakash S, Brahmbhatt KJ, Chawda NT, Tandon N. Hemicrania continua responsive to intravenous methylprednisolone. Headache49, 604–607 (2009).
   Google Scholar
• Wolkowitz OM, Papadopoulos NM, Costello R et al. Prednisone effects on blood–brain barrier permeability and CNS IgG synthesis in healthy humans. Psychoneuroendocrinology15, 155–158, (1990).
   Google Scholar
• Kim G-M, Jin K-S, Chung C-S. Differential effects of corticosteroids on the expression of cyclooxygenase-2, tumour necrosis factor-α and matrix metalloproteinase-9 in an animal model of migraine. Cephalalgia28, 1179–1187 (2008).
   Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd edition. Cephalalgia24(Suppl. 1), 9–160 (2004).
   PubMed Web of Science ®Google Scholar
• Welch KMA. Migraine. A biobehavioral disorder. Arch. Neurol.44, 323–327 (1987).
   PubMedGoogle Scholar
• Gupta VK. A clinical review of the adaptive potential of vasopressin in migraine. Cephalalgia17, 561–569 (1997).
   PubMed Web of Science ®Google Scholar
• Valiquette G. The neurohypophysis. Neurol. Clin.5, 291–331 (1987).
   Google Scholar
• Guedes RC, Frade SF. Effect of ethanol on cortical spreading depression. Braz. J. Med. Biol. Res.26, 1241–1244 (1993).
   PubMed Web of Science ®Google Scholar
• Welch KMA, D’Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol. Clin.8(4), 817–828 (1990).
   PubMed Web of Science ®Google Scholar
• Zhang ET, Hansen AJ, Wieloch T, Lauritzen M. Influence of MK-801 on brain extracellular calcium and potassium activities in severe hypoglycemia. J. Cereb. Blood Flow Metab.10(1) 136–139 (1990).
   Google Scholar
• Dzwonek J, Rylski M, Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett.567, 129–135 (2004).
   PubMed Web of Science ®Google Scholar
• Chandler S, Miller KM, Clements JM et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol.72, 155–161 (1997).
   PubMed Web of Science ®Google Scholar
• Harik SI, Kalaria RN. The blood–brain barrier: a selective overview. In: Cerebrovascular Diseases. Ginsberg MD and Dietrich WD (Eds). Raven, NY, USA 407–410 (1989).
   Google Scholar
• Yong VW, Power C, Forsyth PA et al. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci.2, 502–511 (2001).
   PubMed Web of Science ®Google Scholar
• Yong VW, Krekoski CA, Forsyth PA et al. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci.21, 75–80 (1998).
   PubMed Web of Science ®Google Scholar
• Oh LYS, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J. Neurosci.19, 8464–8475 (1999).
   PubMed Web of Science ®Google Scholar
• Gottschall PE, Deb S. Regulation of matrix metalloproteinase expression in astrocytes, microgila and neurons. Neuroimmunomodulation3, 69–75 (1996).
   PubMed Web of Science ®Google Scholar
• Reynolds MA, Kirchick HJ, Dahlen JR et al. Early biomarkers of stroke. Clin. Chem.49, 1733–1739 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia39, 279–291 (2002).
   PubMed Web of Science ®Google Scholar
• Asahi M, Wang X, Mori T et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia. J. Neurosci.21, 7724–7732 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenberg GA, Cunnigham LA, Wallace J et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res.893, 104–112 (2001).
   PubMed Web of Science ®Google Scholar
• Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache48, 135–139 (2007).
   Google Scholar
• Leira R, Sobrino T, Rodríguez-Yáñez M, Blanco M, Arias S, Castillo J. MMP-9 immunoreactivity in acute migraine. Headache47, 698–702 (2007).
   Google Scholar
• Perini F, D’Andrea G, Galloni E et al. Plasma cytokine levels in migraineurs and controls. Headache45, 926–931 (2005).
   PubMed Web of Science ®Google Scholar
• Ishizaki K, Takeshima T, Fukuhara Y et al. Increased plasma transforming growth factor-β 1 in migraine. Headache45, 1224–1228 (2005).
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Xu Z-Z, Wang X et al. Distinct role of matrix metalloproteinases in the early- and late-phase development of neuropathic pain. Nat. Med.14, 331–336 (2008).
   PubMed Web of Science ®Google Scholar
• Nagase H, Woessner JF. Matrix metalloproteinases: a minireview. J. Biol. Chem.274, 21491–21494 (1999).
   PubMed Web of Science ®Google Scholar
• Zhao B-Q, Wang S, Kim H-Y et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med.12, 441–445 (2006).
   PubMed Web of Science ®Google Scholar
• Chattaopadhyay S, Myers R, Janes J, Shubayev V. Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve. Brain Behav. Immun.21, 561–568 (2007).
   Google Scholar
• Sheen P, O’Kane CM, Chaudhary K et al. High MMP-9 activity characterizes pleural tuberculosis correlating with granuloma formation. Eur. Respir. J.33, 134–141 (2009).
   PubMed Web of Science ®Google Scholar
• Price NM, Farrar J, Tran TT et al. Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J. Immunol.166, 4223–4230 (2001).
   Google Scholar
• Harris JE, Nuttall RK, Elkington PT et al. Monocyte-astrocyte networks regulate matrix metalloproteinase gene expression and secretion in central nervous system tuberculosis in vitro and in vivo. J. Immunol.178, 1199–1207 (2007).
   PubMed Web of Science ®Google Scholar
• Kruit MC, van Buchem MA, Hofman PA et al. Migraine as a risk factor for subclinical brain lesions. JAMA291, 427–434 (2004).
   PubMed Web of Science ®Google Scholar
• Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Brain stem and cerebellar hyperintense lesions in migraine. Stroke37, 1109–1112 (2006).
   PubMed Web of Science ®Google Scholar
• Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain128, 2068–2077 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta V. Silent or non-clinical infarct-like lesions in the posterior circulation territory in migraine: brain hypoperfusion or hyperperfusion? Brain129, E39 (2006).
   PubMedGoogle Scholar
• Gupta VK. White matter hyperintensities: pearls and pitfalls in interpretation of MRI abnormalities. Stroke35, 2756–2757 (2004).
   PubMed Web of Science ®Google Scholar
• Rozen TD. Vanishing cerebellar infarcts in a migraine patient. Cephalalgia27, 557–560 (2007).
   Google Scholar
• Agarwal S, Magu S, Kamal K. Reversible white matter abnormalities in a patient with migraine. Neurol. India56, 182–185 (2008).
   Google Scholar
• Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ330, 63 (2005).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Joseph R, Rose FC. Migraine is not a platelet disorder. Headache25, 434–440 (1985).
   Google Scholar
• Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case–control study. BMJ338, B 664 (2009).
   Google Scholar
• MacClellan LR, GilesW, Cole J et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke38, 2407–2408 (2007).
   Google Scholar
• May A. Morphing voxels: the hype around structural imaging of headache patients. Brain132(Pt 6), 1419–1425 (2009).
   PubMed Web of Science ®Google Scholar
• Parsons AA. Cortical spreading depression: its role in migraine pathogenesis and possible therapeutic intervention strategies. Curr. Pain Headache Rep.8, 410–416 (2004).
   Google Scholar
• Bates EA, Nikai T, Brennan KC et al. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia DOI 10.1111/j.1468- 2982.2009.01864.x (2009) (Epub ahead of print).
   Google Scholar
• Wolthausen J, Sternberg, Gerloff C, May A. Are cortical spreading depression and headache in migraine causally linked? Cephalalgia29, 244–249 (2009).
   PubMed Web of Science ®Google Scholar
• Stankewitz A, May A. The phenomenon of changes in cortical excitability in migraine is not migraine-specific – a unifying thesis. Pain145(1–2), 14–17 (2009).
   Google Scholar
• Richter F, Mikulik O, Ebersberger A et al. Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat – a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J. Cereb. Blood Flow Metab.25, 1225–1235 (2005).
   PubMed Web of Science ®Google Scholar
• Dodick DW. Tonabersat for migraine prevention: new life or last gasp? Lancet Neurol.8, 693–695 (2009).
   Google Scholar
• Dodick DW. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache43(Suppl. 1), 25–33 (2003).
   Google Scholar
• Dowson AJ, Mullen N, Peatfield R et al. Migraine Intervention with STARFlex Technology trial: a prospective, multicentre, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation117, 1397–1404 (2008).
   PubMed Web of Science ®Google Scholar
• Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes – prolonged effects from a single injection. Pain122, 126–129 (2006).
   PubMed Web of Science ®Google Scholar
• Behin F, Lipton RB, Bigal M. Migraine and intranasal contact point headache: is there any connection? Curr. Pain Headache Rep.10(4) 312–315 (2007).
   Google Scholar
• Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache42(6), 519–522 (2002).
   PubMed Web of Science ®Google Scholar
• Robbins LD. Intravenous valproate for prolonged migraine headache. Headache40, 427 (2000).
   Google Scholar
• Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache49(2) 216–226 (2009).
   PubMed Web of Science ®Google Scholar
• Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D’Souza J. Oxcarbazepine in migraine headache. A double-blind, randomized, placebo-controlled study. Neurology70, 548–555 (2008).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Aoki KR. Botulinum toxin type A: myths, facts, and current research. Headache43(Suppl. 1) 1 (2003).
   Google Scholar
• Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache40, 445–450 (2000).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Mauskop A, Elkind AH et al.; BOTOX CDH study group. Botulinum toxin type A for the prophylaxis of chronic daily headache. Subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo- controlled study. Headache45(4) 315–324 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta VK. Botulinum toxin: a treatment for migraine? A systematic review. Pain Med.7, 386–394 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta VK. Botulinum toxin type A therapy for chronic tension-type headache: fact versus fiction. Pain116, 166–167 (2005).
   Google Scholar
• Schulte-Mattler WJ, Karack P, BoNTTH study group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain109, 110–114 (2004).
   PubMed Web of Science ®Google Scholar
• Schulte-Mattler WJ, Karack P. Response to Gupta VK: Botulinum toxin type A for chronic tension-type headache: fact versus fiction. Pain116, 167 (2005).
   Google Scholar
• Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache44(1) 35–42 (2004).
   PubMed Web of Science ®Google Scholar
• Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache48(6) 900–913 (2008).
   PubMed Web of Science ®Google Scholar
• Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology67, 241–245 (2006).
   PubMedGoogle Scholar
• Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol.64(3) 274–284 (2008).
   PubMed Web of Science ®Google Scholar
• Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain141, 60–69 (2009).
   PubMed Web of Science ®Google Scholar
• Gupta VK. Patent foramen ovale closure: science, quasi-science, and empiricism. Cardiology113, 108–110 (2009).
   PubMed Web of Science ®Google Scholar
• Adams HP. Patent foramen ovale: paradoxical embolism and paradoxical data. Mayo Clin. Proc.79, 15–20 (2004).
   PubMed Web of Science ®Google Scholar
• Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; PFO in cryptogenic stroke (PICSS) investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation105, 2625–2631 (2002).
   PubMed Web of Science ®Google Scholar
• Berdat PA, Chatterjee T, Pfammatter JP, Windecker S, Meier B, Carrel T. Surgical management of complications after transcatheter closure of an atrial septal defect or patent foramen ovale. J. Thorac. Cardiovasc. Surg.120, 1034–1039 (2000).
   PubMed Web of Science ®Google Scholar
• Humphrey PPA. The discovery and development of triptans, a major therapeutic breakthrough. Headache48, 685–687 (2008).
   PubMed Web of Science ®Google Scholar
• Burstein R, Jakubowski M, Levy D. Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. Pain115, 21–28 (2005).
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache. Evidence-based review. Neurology70, 1555–1563 (2008).
   PubMed Web of Science ®Google Scholar
• Nikai T, Basbaum AI, Ahn AH. Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan. Pain139, 533–540 (2008).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int. J. Clin. Pract.60(6), 698–706 (2006).
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener H-C, Husstedt IW et al. for the BIBN 4096 BS Clinical Proof of Concept study group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med.350, 1104–1110 (2004).
   PubMed Web of Science ®Google Scholar
• Durham PL. CGRP-receptor antagonists – a fresh approach to migraine therapy? N. Engl. J. Med.350(11), 1073–1075 (2004).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol.142, 1171–1181 (2004).
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial. Lancet372(9656) 2115–2123 (2008).
   PubMed Web of Science ®Google Scholar
• Brain SD. Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine. Br. J. Pharmacol.142, 1053–1054 (2004).
   Google Scholar
• Friedman BW, Corbo J, Lipton RB et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology64, 463–468 (2005).
   Google Scholar
• Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomized controlled trials. BMJ329, 1369–1373 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Stone AM, Lainez MJA, Sawyer JPC. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) study: a randomized trial. JAMA284, 2599–2605 (2000).
   PubMed Web of Science ®Google Scholar
• Edmeads J. What is migraine? Controversy and stalemate in migraine pathophysiology. J. Neurol.238, S2–S3 221 (1991).
   Google Scholar
• van Pragg HM, Lader MH, Rafaelsen OJ, Sachar EJ. Handbook of Biological Psychiatry. Marcel Dekker, NY, USA (1979).
   Google Scholar
• Cady RK. The future of migraine: beyond just another pill. Mayo Clin. Proc.84(5) 397–399 (2009).
   Google Scholar
• Feinstein AR. Clinical judgment revisited: the distraction of quantitative models. Ann. Intern. Med.120, 799–805 (1994).
   PubMed Web of Science ®Google Scholar
• Herman J. Experiment and observation. Lancet344, 1209–1211 (1994).
   PubMed Web of Science ®Google Scholar
• Horton RC, Kendall MJ. Clinical pharmacology and therapeutics. Postgrad. Med. J.67, 1042–1054 (1991).
   PubMed Web of Science ®Google Scholar
• Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonerbasat on migraine with aura: a randomized, double-blind, placebo-controlled crossover study. Lancet Neurol.8(8), 718–723 (2009).
   PubMed Web of Science ®Google Scholar
• Marincola FM. In support of descriptive studies: relevance to translational research. J. Transl. Med.5, 21 (2007).
   PubMed Web of Science ®Google Scholar